In this study safety and tolerability of escalating doses of AZX100 will be evaluated in healthy adult male subjects. A placebo control arm is included in this Phase I study for comparison of injection sites. Approximately 30 adult subjects will be enrolled at an experienced inpatient Phase I study clinic. The primary objective is to evaluate the initial safety and tolerability of AZX100 drug product in healthy adult subjects.
Randolph Steer, president of OrthoLogic, said: “We are pleased that dosing has begun in our AZX100 Phase I human clinical trial program in dermal scarring. The goal of our program for AZX100 is to develop a safe and effective medication for an unmet market need, and it is gratifying to be on track with our announced timelines.”